Logo for EpiBone

Meet an Unreasonable Venture

EpiBone

Creating bone tissue from a patient's mesenchymal stem cells in vitro for use in bone grafts.

Photo of Nina Tandon

Nina Tandon

CEO & Co-Founder at EpiBone

More about Nina »
Employees 21–50
Headquarters Jersey City, New Jersey, United States
EpiBone, Inc. is privately-held clinical-stage regenerative medicine company focused on skeletal reconstruction. Sitting at the intersection of biology and engineering, the company harnesses the power of cells to create living solutions that can become a seamless part of a patient’s body. EpiBone is currently developing a pipeline of bone, cartilage, and compound (bone and cartilage) products.

Notable Achievements

  • IND approval by the FDA in July 2023 to go into Ph 1/2 clinical trials with our cartilage product.
  • Successful completion of our Ph 1/2 clinical trial of our bone product in August 2023.
  • $45.8M of equity funding and $3M in grant funding raised to date.

Currently Operating in Six Regions

Press Mentions

October 17, 2015

Why Peter Thiel Invested In New York Biotech Startup EpiBone

Read on Inc.com »

October 25, 2023

Behind Nina Tandon — The Big Apple and the Biotech Founder

Read on Brown Girl Magazine »

July 24, 2023

EpiBone to Start Clinical Trials for Knee Cartilage Grown in Lab

Read on PRNewswire »

March 9, 2023

EpiBone, emerging biotech company, is relocating to Jersey City — and bringing nearly 100 jobs | ROI-NJ

Read on ROI-NJ »

More Ventures in Health

Get the Unreasonable Newsletter

Get monthly updates on EpiBone and over 396 other ventures working to solve the world's toughest problems.

Read our Privacy Policy.